Clinical Research Directory

Inclusion Criteria: * Chronic foot ulcer (\> 1month) (at or below the ankle) grade 1A, 2A (University of Texas Wound Classification System) with an ulcer area between 150-350 mm2. * No ulcer should present a moderate or severe infection at baseline. Concomitant treatment with systemic antibiotics at baseline is accepted if all ulcers meet none of the criteria defining moderate or severe infection. * Toe/brachial index \>0.6 and/or Tcp02 \>50mmHg or ankle/brachial index \>0.65, or the pulses at dorsalis pedis/tibialis posterioris clearly palpable. * If more than one ulcer is present, the largest ulcers that fulfill inclusion criteria will be included * Patient should be compliant to one of the accepted off-loading system. * Patients will be able to provide written informed consent Exclusion Criteria: * Acute cardiovascular event (myocardial infarction/unstable angina, stroke) within three months prior to randomisation * Subjects who have undergone vascular reconstruction or angioplasty less than 3 months prior to randomisation * Decompensated congestive heart failure or functional class 3-4. * Childbearing potential * Impaired hepatic function (2 times upper normal limit of ASAT and ALAT) * Severe renal failure (GFR calculated after Cockcroft's formula \<30 ml/min/1.73 m2) * Ongoing treatment with immunosuppressive drugs * HbA1c \>12 % (108 mmol/l)(12%) * Polyglobulia (EVF\>0.60 men, EVF\> 0.56 women) * Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol * Malignancy other than basal-cell carcinoma and cervical carcinoma in situ, requiring any general, local, surgical or radiation therapy. * History of alcohol or drug abuse * Osteomyelitis defined as: 1. There is a clinical suspicion of osteomyelitis; 2. Ulcer considered for treatment is located at the site of a past amputation; 3. History of acute osteomyelitis in the past 90 days or history of recurrent osteomyelitis; or 4. A positive "probe to bone" test. * Participant in another ongoing study * Known hypersensitivity to deferoxamine * Unwillingness to participate following oral and written information * Subjects with any other severe acute or chronic medical or psychiatric condition that make the subject inappropriate for the study in the judgment of the investigator.